Radiologic surveillance of patients with viral hepatitis by Sohail, Saba
eCommons@AKU 
Department of Radiology Medical College, Pakistan 
8-2017 
Radiologic surveillance of patients with viral hepatitis 
Saba Sohail 
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_radiol 
 Part of the Radiology Commons, and the Virus Diseases Commons 
Viral hepatitis remains a cause of great health concern
globally. With an approximate burden of HBV from
3 - 7.3%, HCV from 2.2 - 5.2%, and 7.6% for hepatitis B
and C and even higher for selected groups,1 for a
population of approximate 207.77 million, Pakistan is no
exception.
These hepatitides tend to run a protracted course in a
large number of patients. Despite the advances in
vaccination of HBV, there are a sizeable number of
patients encountered in everyday clinical practice who
have either active viremia or severe fibrosis, cirrhosis
and portal hypertension (PHT) in spite of a sustained
viral response (SVR). The main key factor is ongoing
hepatic fibrosis progressing to cirrhosis and its
complications. Surveillance, therefore, has to be done
for progression of fibrosis, which appears to be a
decisive factor in determining the extent of hepatic
damage, ending up in hepatocellular carcinoma (HCC).
This has an all-important bearing on the management
and final outcome of disease.
There is no disagreement about the need for surveillance.
Disputable points are: whom, how and when?
Consensus guidelines vary according to age, gender,
viral genotypes (in case of HCV), mono- or dual-
infection, and the presence of complications. Very
broadly speaking, alcoholic persons with active
HBV+HCV, appear to be at greater risk of cirrhosis.2,3
Studies indicate that achieving SVR with Direct Acting
Antivirals (DAAs) does not abolish the risk of HCC,
cirrhosis and PHT, so that these patients must be
followed up.4
The next question is: how to perform this surveillance.
Clinical and laboratory parameters have led to formulate
many indices and combinations (ARRI, Fibrotest and
FIB-4, for instance) with age, platelet indices, liver
enzymes and tumor markers (AFP), which reflect
functional outcome of the physical change in liver. This
morphological change is ideally evaluated by biopsy,
which is an invasive test with attendant albeit slight risk
of morbidity and mortality; but greater is the fractional
representation in the sample from a very large organ
resulting in interpretative errors. Hence, blood tests and
radiologic imaging combination are gaining popularity to
achieve this end.
Currently, fibrosis is basically evaluated with sonoelasto-
graphy, also called transient elastography or The
Elastography, which has been in practice for over a
decade and, is widely available even in Pakistan and is
said to have a rather accurate correlation with the
histologic stage of fibrosis than the gray-scale or even
Doppler sonography.5 Then main advantage of the latter
is identification of steatosis6 and detection of small HCC.
Magnetic resonance elastography (MRE) is considered
superior to sonoelastography. It is a single custom-
tailored study with dedicated protocol that measures
fibrosis as well as the fat and iron content of liver in a
much larger hepatic tissue, thus overcoming the
heterogeneity of change, and observer bias.7
Advanced fibrosis leads to cirrhosis, PHT and HCC.
Conventional abdominal ultrasound, including gray-
scale and Doppler scan, is as good for detection and
monitoring of PHT as any clinician may wish. Likewise,
it is also good for detection of small mass lesions in early
HCC.8 It is now recommended from the American and
European experience that surveillance for HCC should
be done at a 6-monthly interval through abdominal
ultrasound.8-10 Shorter (3-month) and longer (one-year)
intervals have been experimental with; but the yield and
outcome of the bi-annual sonography reward the most
practical and cost-effective approach.11,12 CT is not
preferred due to cost and radiation.13
So to conclude, women older than 50 years and men
aged above 40 years having single and dual hepatitis
viral infection, irrespective of active or quiescent
infection or even SVR, should undergo a 6-monthly
monitoring with simpler blood tests coupled with hepatic
sonography (conventional ± sonoelastography); and
those with a detectable nodule must undergo further
evaluation. MR holds greater promise, but at a greater
financial cost and with limited availability. The need of
the hour is to develop local surveillance guidelines
tailored to Pakistani/regional needs, which is rather
deficient at present.
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